Michael C Cox

Michael C Cox

UNVERIFIED PROFILE

Are you Michael C Cox?   Register this Author

Register author
Michael C Cox

Michael C Cox

Publications by authors named "Michael C Cox"

Are you Michael C Cox?   Register this Author

26Publications

272Reads

36Profile Views

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.

Pediatr Blood Cancer 2018 10 12;65(10):e27271. Epub 2018 Jun 12.

Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27271DOI Listing
October 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.

Invest New Drugs 2007 Feb 25;25(1):63-7. Epub 2006 Aug 25.

Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Heath, Bldg 8, Rm 5101, 8901 Wisconsin Ave, Bethesda, MD 20889-5015, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-006-9006
Web Search
http://link.springer.com/10.1007/s10637-006-9006-7
Publisher Site
http://dx.doi.org/10.1007/s10637-006-9006-7DOI Listing
February 2007

The use of thalidomide in androgen-independent prostate cancer.

Urol Oncol 2006 May-Jun;24(3):246-9

Clinical Pharmacology Research Core, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2005.11.020DOI Listing
October 2006

Emerging drugs to replace current leaders in first-line therapy for breast cancer.

Expert Opin Emerg Drugs 2006 Sep;11(3):489-501

National Cancer Institute - National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14728214.11.3.48
Publisher Site
http://dx.doi.org/10.1517/14728214.11.3.489 DOI Listing
September 2006

Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.

Clin Cancer Res 2006 Aug;12(15):4636-40

Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland 20889, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0388DOI Listing
August 2006

Thalidomide metabolism and hydrolysis: mechanisms and implications.

Curr Drug Metab 2006 Aug;7(6):677-85

Clinical Pharmacology Research Core, SAIC-Frederick, Inc., NCI-Frederick, Maryland, 21702, USA.

View Article

Download full-text PDF

Source
August 2006

Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.

Cancer 2006 Jan;106(1):63-7

Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.21576DOI Listing
January 2006

Antiangiogenesis: a possible treatment option for prostate cancer?

Clin Genitourin Cancer 2005 Dec;4(3):197-202

Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CGC.2005.n.033DOI Listing
December 2005

Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.

Urology 2005 Sep;66(3):571-6

Department of Radiation Oncology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2005.03.083DOI Listing
September 2005

Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?

Expert Rev Anticancer Ther 2005 Aug;5(4):605-11

Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bldg 10, Rm 5A01, MSC 1910, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.5.4.605DOI Listing
August 2005

Angiogenesis and prostate cancer: important laboratory and clinical findings.

Curr Oncol Rep 2005 May;7(3):215-9

National Cancer Institute, 10 Center Drive, Building 10, Room 5A-01, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
May 2005

Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.

World J Urol 2004 Dec 8;22(6):425-30. Epub 2004 Dec 8.

Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-004-0443-7
Publisher Site
http://dx.doi.org/10.1007/s00345-004-0443-7DOI Listing
December 2004

Herbal remedies in the United States: potential adverse interactions with anticancer agents.

J Clin Oncol 2004 Jun;22(12):2489-503

Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.08.182DOI Listing
June 2004

No rational theory for drug pricing.

J Clin Oncol 2004 Mar;22(5):962-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.99.318DOI Listing
March 2004

Pharmacy education: back to the basics?

Pharmacotherapy 2003 Nov;23(11):1381-90

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.23.14.1381.31946DOI Listing
November 2003

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Ann Pharmacother 2003 Oct;37(10):1369-74

Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1C404DOI Listing
October 2003

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

Cancer Biol Ther 2002 Nov-Dec;1(6):669-73

Molecular Pharmacology Section, Cancer Therapeutic Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.318DOI Listing
June 2003

National Cancer Institute intramural approach to advanced prostate cancer.

Clin Prostate Cancer 2002 Dec;1(3):153-62

Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
December 2002